Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
ObjectiveTo report the occurrence of urologic complications in women undergoing surgery for placenta accreta spectrum (PAS) disorders.MethodsMedline, Embase and Cochrane databases were searched electronically up to 1st of November 2022. Studies reporting cohort on surgical management and outcome of PAS. Two independent reviewers performed the data extraction using a predefined protocol and assessed the risk of bias using the Newcastle‐Ottawa scale for observational studies, with difference agreed by consensus. The primary outcome was the overall occurrence of urologic complications in women undergoing surgery for PAS. Secondary outcomes were overall cystotomy, intentional cystotomy, unintentional cystotomy, ureteral damage, ureteral fistula, vesicovaginal fistula. All these outcomes were explored in the overall population of patients undergoing hysterectomy for PAS disorders. In addition, we performed sub‐group analyses according to the severity of PAS at histopathology (placenta accreta/increta and percreta), type of intervention (planned vs emergency), ureteral stent placing and number of cases per year. Random‐effect meta‐analyses of proportions were used to analyze the data.ResultsSixty‐two studies were included. Urologic complications occurred in 15.29% (95% CI, 13.0‐17.2) of cases. Cystotomy complicated 13.02% (95% CI, 9.2‐17.3) of surgical operations. Intentional cystotomy was required in 5.58% (95% CI, 2.7‐9.3) of cases while damage to the bladder occurred in 7.40% (95% CI, 4.3‐11.2) of cases. Urologic complications occurred in 19.36% (95% CI, 16.3‐22.7) of cases undergoing hysterectomy and 12.22% (95% CI, 7.5‐17.8) of those having conservative treatment. In the sub‐group analyses, urologic complications occurred in 9.42% (95% CI, 5.4‐14.4) of women with placenta accreta‐increta and 38.52% (95% CI, 21.6‐57.0) of those described as placenta percreta and were mainly represented by cystotomy (5.53% (95% CI, 0.6‐15.1) in women with placenta accreta increta and 21.97% (95% CI, 15.4‐45.5) in the placenta percreta subgroup). Urologic complications occurred in 15.44% (95% CI, 8.1‐24.6) during planned procedures and in 24.61% (95% CI, 13.0‐38.5) during emergency intervention. The incidence of urologic complications was similar to that reported in the primary analysis in studies reporting >10 cases per year.ConclusionsPatients undergoing surgery for PAS disorders are at high‐risk of urologic complications, mainly cystotomy. The incidence of these complications is higher in patients described as having a placenta percreta at birth and in case of emergency surgical intervention. The high heterogeneity highlights the need to use standardized protocols for the diagnosis of PAS to identify prenatal imaging signs associated with a risk of urologic morbidity at delivery.This article is protected by copyright. All rights reserved.
ObjectiveTo report the occurrence of urologic complications in women undergoing surgery for placenta accreta spectrum (PAS) disorders.MethodsMedline, Embase and Cochrane databases were searched electronically up to 1st of November 2022. Studies reporting cohort on surgical management and outcome of PAS. Two independent reviewers performed the data extraction using a predefined protocol and assessed the risk of bias using the Newcastle‐Ottawa scale for observational studies, with difference agreed by consensus. The primary outcome was the overall occurrence of urologic complications in women undergoing surgery for PAS. Secondary outcomes were overall cystotomy, intentional cystotomy, unintentional cystotomy, ureteral damage, ureteral fistula, vesicovaginal fistula. All these outcomes were explored in the overall population of patients undergoing hysterectomy for PAS disorders. In addition, we performed sub‐group analyses according to the severity of PAS at histopathology (placenta accreta/increta and percreta), type of intervention (planned vs emergency), ureteral stent placing and number of cases per year. Random‐effect meta‐analyses of proportions were used to analyze the data.ResultsSixty‐two studies were included. Urologic complications occurred in 15.29% (95% CI, 13.0‐17.2) of cases. Cystotomy complicated 13.02% (95% CI, 9.2‐17.3) of surgical operations. Intentional cystotomy was required in 5.58% (95% CI, 2.7‐9.3) of cases while damage to the bladder occurred in 7.40% (95% CI, 4.3‐11.2) of cases. Urologic complications occurred in 19.36% (95% CI, 16.3‐22.7) of cases undergoing hysterectomy and 12.22% (95% CI, 7.5‐17.8) of those having conservative treatment. In the sub‐group analyses, urologic complications occurred in 9.42% (95% CI, 5.4‐14.4) of women with placenta accreta‐increta and 38.52% (95% CI, 21.6‐57.0) of those described as placenta percreta and were mainly represented by cystotomy (5.53% (95% CI, 0.6‐15.1) in women with placenta accreta increta and 21.97% (95% CI, 15.4‐45.5) in the placenta percreta subgroup). Urologic complications occurred in 15.44% (95% CI, 8.1‐24.6) during planned procedures and in 24.61% (95% CI, 13.0‐38.5) during emergency intervention. The incidence of urologic complications was similar to that reported in the primary analysis in studies reporting >10 cases per year.ConclusionsPatients undergoing surgery for PAS disorders are at high‐risk of urologic complications, mainly cystotomy. The incidence of these complications is higher in patients described as having a placenta percreta at birth and in case of emergency surgical intervention. The high heterogeneity highlights the need to use standardized protocols for the diagnosis of PAS to identify prenatal imaging signs associated with a risk of urologic morbidity at delivery.This article is protected by copyright. All rights reserved.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.